Rhythm Pharmaceuticals Inc (NASDAQ:RYTM)

7.28
Delayed Data
As of Jan 21
 -0.31 / -4.08%
Today’s Change
7.21
Today|||52-Week Range
43.26
-27.05%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$453.9M

Company Description

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Contact Information

Rhythm Pharmaceuticals, Inc.
222 Berkeley Street
Boston Massachusetts 02116
P:(857) 264-4280
Investor Relations:
(857) 254-4489

Employees

Shareholders

Individual stakeholders66.73%
Mutual fund holders47.60%
Other institutional35.41%

Top Executives

David P. MeekerChairman, President & Chief Executive Officer
Hunter C. SmithChief Financial Officer & Treasurer
Alastair GarfieldHead of Research
Brieana BuckleyVice President-Medical Affairs
Joseph ShulmanSenior Vice President-Technical Operations